Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab

Taxiarchis V. Kourelis, Brad S. Kahl, Peter Benn, Judith A. Delach, Syed F. Bilgrami

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Herein, we describe a case of a female patient in whom B cell chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) were diagnosed simultaneously. She presented with anemia, thrombocytopenia and splenomegaly. Flow cytometry demonstrated two immunophenotypically distinct CD5-positive monoclonal B cell populations. Peripheral blood fluorescence in situ hybridization (FISH) was positive for IGH/CCND1, consistent with t(11;14) translocation. She received 6 cycles of bendamustine 70 mg/m2/day for 2 days and rituximab on the first day every 4 weeks along with granulocyte-colony stimulating factor. She had an excellent response, and repeat computed tomography after her third cycle of chemotherapy revealed no organomegaly or lymphadenopathy. Her peripheral blood lymphocytosis also resolved. Bone marrow examination revealed no detectable flow-cytometric evidence of MCL or CLL. Repeat cytogenetic and FISH analysis were also normal. The patient remains in complete remission 20 months after her initial diagnosis and is receiving maintenance rituximab 375 mg/m2 weekly for 4 weeks every 6 months for 2 years.

Original languageEnglish (US)
Pages (from-to)40-43
Number of pages4
JournalActa Haematologica
Issue number1
StatePublished - Jun 2011


  • Bendamustine
  • Mantle cell lymphoma
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab'. Together they form a unique fingerprint.

Cite this